Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs – Xconomy
|
Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs
Xconomy OncoMed Pharmaceuticals (NASDAQ: OMED) may be a long ways away from actually winning FDA approval of a product, but it just got a big vote of confidence from Celgene that it’s on the right track with its cancer stem cell work. Celgene (NASDAQ: CELG) … OncoMed, Celgene To Jointly Advance Multiple Anti-Cancer Stem Cell …NASDAQ Celgene commits $3.3B in whopper cancer stem cell deal with OncoMedFierceBiotech OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple …GlobeNewswire (press release) Reuters India all 17 news articles |
